S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ADCT · ADC Therapeutics SA
NEW YORK STOCK EXCHANGE, INC. - BOATS Real Time Price • USD
ADC Therapeutics SA (ADCT)
NEW YORK STOCK EXCHANGE, INC.
Biotechnology
$1.50
-0.02
(-0.99%)
● At close: October 21 at 4:00:00 PM EDT
$1.49
-0.01
(-0.67%)
Overnight:
1:23:52 AM EDT
DAY'S RANGE
$1.50
$1.45
$1.54
52-WEEK RANGE
$1.50
$0.78
$4.98
What's happening
- ADCT is down 0.99% today, trading at $1.50. — Live quote
- Volume today (107,412) is well below its 3-month average of 1,516,930. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.09 actual vs. $-0.22 estimated (+58.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 4
Hold 3
Sell 0
Strong sell 1
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ADCT
-56.94%
vs S&P 500
-69.72%
1-YEAR RETURN
ADCT
-64.57%
vs S&P 500
-79.13%
6-MONTH RETURN
ADCT
-65.30%
3-MONTH RETURN
ADCT
+19.68%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.09
Est. $-0.22
BEAT +58.4%
2026-04-26 (Q1 2026)
$-0.13
Est. $-0.22
BEAT +40.7%
2026-01-26 (Q4 2025)
$-0.04
Est. $-0.27
BEAT +85.4%
2025-10-26 (Q3 2025)
$-0.30
Est. $-0.37
BEAT +18.7%
Valuation Measures & Ratios
Enterprise Value4$391.1M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)2.44
Price / Book74.17
EV4 / Revenue4.91
EV4 / EBITDA—
Profit Margin-121.77%
Operating Margin-125.08%
Return on Equity (ROE8)-229.23%
Return on Assets (ROA9)-32.75%
Avg Volume (3M)1,516,930
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $159.6M | $587.9M | $547.6M | $304.8M | $150.7M |
| P/E | -1.08 | -3.48 | -3.04 | -1.73 | -0.91 |
| Price/Sales | 2.12 | 7.43 | 7.13 | 3.92 | 1.96 |
| Price/Book | -0.70 | -2.72 | -2.30 | -1.53 | -0.63 |
| EV/Revenue | -0.71 | 4.57 | 4.08 | 0.52 | -0.57 |
| ROE | 64.48% | 78.19% | 75.65% | 88.24% | 69.57% |
| ROA | -52.67% | -58.04% | -62.18% | -54.66% | -60.81% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short6,896,051
Change from Prior Settlement+27.93%
% of Float—
Days to Cover (Short Ratio)4.37
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 2.2% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -121.8%. Finnhub fundamentals ↗
- Trailing 52-week price return is -64.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ADCT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.2M | $20.9M | $16.4M | $18.8M | $23.0M | $18.5M | $17.4M | $18.1M |
| Operating income | -$25.4M | -$25.2M | -$31.0M | -$44.1M | -$28.5M | -$35.6M | -$29.0M | -$33.6M |
| Net income | -$16.6M | -$33.0M | -$41.0M | -$56.6M | -$38.6M | -$44.0M | -$36.5M | -$46.6M |
| EPS (diluted) | $-0.11 | $-0.21 | $-0.30 | $-0.50 | $-0.36 | $-0.42 | $-0.38 | $-0.56 |
| EPS (basic) | $-0.11 | $-0.21 | $-0.30 | $-0.50 | $-0.36 | $-0.42 | $-0.38 | $-0.56 |
| Operating margin | -$132 | -$121 | -$189 | -$234 | -$124 | -$193 | -$167 | -$186 |
| Net margin | -$86 | -$158 | -$249 | -$301 | -$168 | -$238 | -$210 | -$258 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $279.4M | $291.5M | $323.1M | $289.8M | $321.6M | $272.5M | $322.0M | $349.1M |
| Total liabilities | $507.6M | $507.9M | $509.0M | $527.9M | $520.7M | $510.8M | $524.6M | $521.0M |
| Stockholders' equity | -$228.2M | -$216.4M | -$185.8M | -$238.2M | -$199.2M | -$238.2M | -$202.6M | -$171.9M |
| Total current assets | $261.7M | $276.8M | $306.3M | $287.1M | $318.8M | $258.0M | $291.3M | $333.0M |
| Total current liabilities | $86.3M | $67.6M | $70.2M | $62.0M | $64.6M | $57.8M | $80.5M | $67.7M |
| Cash & equivalents | $219.1M | $231.0M | $261.3M | $234.7M | $264.6M | $194.7M | $250.9M | $274.3M |
| Inventory | $4.9M | $4.8M | $4.2M | $18.0M | $17.8M | $17.4M | $2.3M | $16.1M |
| Other current assets | $4.3M | $4.3M | $6.1M | $5.5M | $5.7M | $7.2M | $9.4M | — |
| Property, plant & equipment | — | — | $0 | $0 | $1.0K | $5.2M | $5.1M | $5.7M |
| Other non-current assets | $1.2M | $1.2M | $1.2M | $1.2M | $1.3M | $1.2M | $1.2M | $1.2M |
| Accounts payable | $12.8M | $5.3M | $9.2M | $8.1M | $9.6M | $15.6M | $18.0M | $14.4M |
| Accrued liabilities | $67.4M | $57.7M | $58.0M | $53.9M | $55.0M | $42.2M | $62.4M | $53.3M |
| Short-term debt | $6.2M | $4.6M | $3.0M | — | — | — | $0 | — |
| Other non-current liabilities | $6.2M | $5.0M | $2.8M | $9.4M | $7.2M | $4.4M | $2.4M | $7.6M |
| Common stock & paid-in capital | $11.3M | $11.2M | $11.1M | $9.8M | $9.8M | $8.4M | $8.4M | $8.2M |
| Retained earnings | -$1.69B | -$1.67B | -$1.64B | -$1.63B | -$1.59B | -$1.53B | -$1.49B | -$1.46B |
| Accumulated other comprehensive income (loss) | -$814.0K | -$802.0K | -$517.0K | -$702.0K | -$388.0K | -$1.1M | -$1.4M | $203.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.8M | -$29.7M | -$31.1M | -$29.6M | -$24.1M | -$56.3M | -$21.9M | -$25.0M |
| Investing cash flow | $0 | -$32.0K | $659.0K | $0 | $0 | -$264.0K | -$90.0K | -$216.0K |
| Financing cash flow | -$99.0K | -$583.0K | $57.1M | -$198.0K | $93.8M | $271.0K | -$1.1M | -$879.0K |
| Free cash flow | -$11.8M | -$29.7M | -$31.1M | -$29.6M | -$24.1M | -$56.6M | -$21.9M | -$25.3M |
| Capital expenditures | $0 | $32.0K | $0 | $0 | $0 | $264.0K | $90.0K | $216.0K |
| Share-based compensation | $4.5M | $2.4M | $673.0K | $2.0M | $1.8M | $2.4M | $1.6M | $2.8M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | -$3.0M | $1.9M | $6.2M | -$3.3M | -$5.6M | $11.4M | -$3.7M | $1.3M |
| Change in inventory | $3.3M | -$16.0K | $853.0K | $516.0K | $706.0K | $306.0K | $2.8M | $880.0K |
| Tax withholding on stock comp | $217.0K | $768.0K | $1.3M | $0 | $250.0K | $0 | $1.2M | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Revenue | $81.4M | $70.8M | $69.6M | $209.9M |
| Operating income | -$121.5M | -$130.7M | -$166.0M | -$123.3M |
| Net income | -$142.6M | -$157.8M | -$240.1M | -$157.1M |
| EPS (diluted) | $-1.12 | $-1.62 | $-2.94 | $-2.01 |
| EPS (basic) | $-1.12 | $-1.62 | $-2.94 | $-2.01 |
| Operating margin | -$149 | -$184 | -$239 | -$59 |
| Net margin | -$175 | -$223 | -$345 | -$75 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $323.1M | $322.0M | $354.8M | $490.9M | — |
| Total liabilities | $509.0M | $524.6M | $503.0M | $411.4M | — |
| Stockholders' equity | -$185.8M | -$202.6M | -$148.2M | $79.5M | $154.0M |
| Total current assets | $306.3M | $291.3M | $336.3M | $435.0M | — |
| Total current liabilities | $70.2M | $80.5M | $67.7M | $81.9M | — |
| Cash & equivalents | $261.3M | $250.9M | $278.6M | $326.4M | — |
| Inventory | $4.2M | $2.3M | $16.2M | $12.1M | — |
| Other current assets | $6.1M | $9.4M | $6.0M | — | — |
| Property, plant & equipment | $0 | $5.1M | $5.6M | $3.4M | — |
| Other non-current assets | $1.2M | $1.2M | $711.0K | $902.0K | — |
| Accounts payable | $9.2M | $18.0M | $15.6M | $12.4M | — |
| Accrued liabilities | $58.0M | $62.4M | $52.1M | $68.5M | — |
| Short-term debt | $3.0M | $0 | — | — | — |
| Other non-current liabilities | $2.8M | $2.4M | $8.9M | $838.0K | — |
| Common stock & paid-in capital | $11.1M | $8.4M | $7.3M | $7.3M | — |
| Retained earnings | -$1.64B | -$1.49B | -$1.34B | -$1.10B | — |
| Accumulated other comprehensive income (loss) | -$517.0K | -$1.4M | -$93.0K | $1.8M | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Operating cash flow | -$141.2M | -$123.8M | -$118.7M | -$138.3M |
| Investing cash flow | $395.0K | -$867.0K | -$3.2M | -$687.0K |
| Financing cash flow | $150.9M | $97.1M | $73.9M | -$897.0K |
| Free cash flow | -$141.4M | -$124.7M | -$121.9M | -$139.0M |
| Capital expenditures | $264.0K | $867.0K | $3.2M | $687.0K |
| Share-based compensation | $6.9M | $6.6M | $13.5M | $49.3M |
| Deferred income taxes | $0 | $0 | $37.1M | -$1.6M |
| Change in accounts receivable | $8.8M | -$4.8M | -$47.8M | $42.8M |
| Change in inventory | $2.4M | $3.7M | $5.7M | $9.7M |
| Tax withholding on stock comp | $1.5M | $1.2M | $0 | $1.3M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ADCT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-13 to 2026-06-30
Recent transactions
- Most recent: Zaki Mohamed (Chief Medical Officer) — Grant / award of 213,900 shares on 2026-06-30.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Zaki Mohamed | Chief Medical Officer | Grant / award | 2026-06-30 | 213,900 |
| GRAHAM PETER J | Chief Legal Officer | Grant / award | 2026-06-30 | 221,100 |
| Carmona Jose | Chief Financial Officer | Grant / award | 2026-06-30 | 203,700 |
| MALLIK AMEET | Chief Executive Officer | Grant / award | 2026-06-30 | 675,000 |
| Azelby Robert | Director | Tax withholding | 2026-06-03 | 12,600 |
| Squarer Ron | Director | Tax withholding | 2026-06-03 | 15,196 |
| Sandor Victor | Director | Tax withholding | 2026-06-03 | 12,600 |
| Monges Viviane | Director | Tax withholding | 2026-06-03 | 2,596 |
| Hug Peter | Director | Tax withholding | 2026-06-03 | 2,156 |
| BIZZARI JEAN-PIERRE | Director | Tax withholding | 2026-06-03 | 12,600 |
| Coughlin Timothy | Director | Tax withholding | 2026-06-03 | 12,600 |
| Redmile Group, LLC | 10% owner | Open market sale | 2026-04-02 | 2,634,506 |
| Kallebo Lisa Michelle | Chief Accounting Officer | Grant / award | 2026-02-13 | 62,900 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-30 | Zaki Mohamed | Chief Medical Officer | Grant / award | 213,900 | $0.00 |
| 2026-06-30 | GRAHAM PETER J | Chief Legal Officer | Grant / award | 221,100 | $0.00 |
| 2026-06-30 | Carmona Jose | Chief Financial Officer | Grant / award | 203,700 | $0.00 |
| 2026-06-30 | MALLIK AMEET | Chief Executive Officer | Grant / award | 675,000 | $0.00 |
| 2026-06-03 | Azelby Robert | Director | Tax withholding | 12,600 | $3.08 |
| 2026-06-03 | Squarer Ron | Director | Tax withholding | 15,196 | $3.08 |
| 2026-06-03 | Sandor Victor | Director | Tax withholding | 12,600 | $3.08 |
| 2026-06-03 | Monges Viviane | Director | Tax withholding | 2,596 | $3.08 |
| 2026-06-03 | Hug Peter | Director | Tax withholding | 2,156 | $3.08 |
| 2026-06-03 | BIZZARI JEAN-PIERRE | Director | Tax withholding | 12,600 | $3.08 |
| 2026-06-03 | Coughlin Timothy | Director | Tax withholding | 12,600 | $3.08 |
| 2026-06-01 | Azelby Robert | Director | Grant / award | 45,000 | $0.00 |
| 2026-06-01 | Squarer Ron | Director | Grant / award | 45,000 | $0.00 |
| 2026-06-01 | Sandor Victor | Director | Grant / award | 45,000 | $0.00 |
| 2026-06-01 | Monges Viviane | Director | Grant / award | 45,000 | $0.00 |
| 2026-06-01 | Hug Peter | Director | Grant / award | 45,000 | $0.00 |
| 2026-06-01 | BIZZARI JEAN-PIERRE | Director | Grant / award | 45,000 | $0.00 |
| 2026-06-01 | Coughlin Timothy | Director | Grant / award | 45,000 | $0.00 |
| 2026-04-02 | Redmile Group, LLC | 10% owner | Open market sale | 2,634,506 | $3.28 |
| 2026-04-02 | Redmile Group, LLC | 10% owner | Open market sale | 2,529,491 | $3.28 |
| 2026-04-01 | Redmile Group, LLC | 10% owner | Open market sale | 169,265 | $3.80 |
| 2026-04-01 | Redmile Group, LLC | 10% owner | Open market sale | 162,517 | $3.80 |
| 2026-03-31 | Redmile Group, LLC | 10% owner | Open market sale | 196,229 | $3.75 |
| 2026-03-31 | Redmile Group, LLC | 10% owner | Open market sale | 188,407 | $3.75 |
| 2026-02-13 | Kallebo Lisa Michelle | Chief Accounting Officer | Grant / award | 62,900 | $3.99 |
| 2026-02-13 | Kallebo Lisa Michelle | Chief Accounting Officer | Tax withholding | 5,433 | $3.99 |
| 2026-02-13 | Zaki Mohamed | Chief Medical Officer | Grant / award | 285,200 | $3.99 |
| 2026-02-13 | Zaki Mohamed | Chief Medical Officer | Tax withholding | 24,603 | $3.99 |
| 2026-02-13 | GRAHAM PETER J | Chief Legal Officer | Grant / award | 294,800 | $3.99 |
| 2026-02-13 | GRAHAM PETER J | Chief Legal Officer | Tax withholding | 33,294 | $3.99 |
| 2026-02-13 | Carmona Jose | Chief Financial Officer | Grant / award | 271,600 | $3.99 |
| 2026-02-13 | Carmona Jose | Chief Financial Officer | Tax withholding | 25,880 | $3.99 |
| 2026-02-13 | MALLIK AMEET | Chief Executive Officer | Grant / award | 900,000 | $3.99 |
| 2026-02-13 | MALLIK AMEET | Chief Executive Officer | Tax withholding | 103,231 | $3.99 |
| 2025-12-06 | MALLIK AMEET | Chief Executive Officer | Tax withholding | 233,146 | $3.29 |
| 2025-12-06 | Zaki Mohamed | Chief Medical Officer | Tax withholding | 41,068 | $3.29 |
| 2025-12-06 | Kallebo Lisa Michelle | Chief Accounting Officer | Tax withholding | 7,140 | $3.29 |
| 2025-12-06 | GRAHAM PETER J | Chief Legal Officer | Tax withholding | 49,508 | $3.29 |
| 2025-12-06 | Carmona Jose | Chief Financial Officer | Tax withholding | 53,236 | $3.29 |
| 2025-06-13 | Squarer Ron | Director | Tax withholding | 15,184 | $3.58 |
| 2025-06-13 | Sandor Victor | Director | Tax withholding | 12,600 | $3.58 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:30 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 8-K | 2026-10-07 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-06-30 | View on SEC.gov → |
| 2026-06-24 | 8-K | 2026-06-24 | View on SEC.gov → |
| 2026-06-03 | 4 | 2026-06-01 | View on SEC.gov → |
| 2026-06-03 | 4 | 2026-06-01 | View on SEC.gov → |
| 2026-06-03 | 4 | 2026-06-01 | View on SEC.gov → |
Recent news
Headlines about ADCT (ADC Therapeutics SA). Links open the publisher — we don’t host full articles.
-
ADC Therapeutics (NYSE:ADCT) - Stock Analysis
Simply Wall Street · 2026-10-17 -
ADC Therapeutics Cuts Debt, Extends Runway Ahead of Key Drug Data, RBC Says
Yahoo Finance · 2026-10-09 -
ADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull Thesis
Seeking Alpha · 2026-10-09 -
ADC Therapeutics undergoes strategic financial restructuring
Seeking Alpha · 2026-10-08 -
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
Yahoo Finance · 2026-10-08 -
ADC Therapeutics SA (ADCT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow
Seeking Alpha · 2026-09-12 -
ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Yahoo Finance · 2026-09-03 -
ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript
Yahoo Finance · 2026-08-20
No headlines in this category right now — try “All”.